Gujarat Intrux Q1 profit up 10% — steady but nothing more
Revenue of ₹14.07 crore and net profit of ₹2.14 crore for the June quarter, with an unmodified audit opinion. A routine update for the ₹152-crore nano-cap.
What's new
- Revenue rose 8% YoY to ₹14.07 crore
- Net profit increased to ₹2.14 crore from ₹1.95 crore
- Auditor gave an unmodified report; no dividend declared
Why this matters
This is a steady but unexciting quarter for Gujarat Intrux. Revenue and profit are both up, but within typical seasonal swings. The zero-debt balance sheet and 16% ROE are positives, but the lack of any strategic catalyst keeps the stock a show-me story.
What we're watching
- Whether revenue growth can sustain above 10% this year
- Any new customer wins or capacity additions
- If margins can expand from current ~15% net margin
The full read
Gujarat Intrux's Q1 FY27 numbers are the definition of steady: revenue of ₹14.07 crore (up 8%), net profit of ₹2.14 crore (up 10%), with an unmodified audit report. The nano-cap manufacturer carries zero debt and posts a 16% ROE, a comfortable foundation. Yet these are incremental gains, not the breakout quarter a ₹152-crore market cap needs to justify a premium valuation. No dividend, no new orders, no strategy shift. Routine filing. The stock trades at 14.7 times trailing earnings, fair for the quality but pricing in no surprises. The next test is whether revenue growth can accelerate or margins widen from here. Until then, this is a show-me story.
Questions answered
- How did Gujarat Intrux's Q1 FY27 results compare to the year-ago quarter?
- Revenue grew 8% from ₹13.03 crore to ₹14.07 crore, while net profit rose 10% from ₹1.95 crore to ₹2.14 crore. The results are in line with prior trends.
- Did the auditor flag any issues in the Q1 results?
- The audit report is unmodified, with only a procedural emphasis of matter on management-certified closing stock. That is a routine observation and does not indicate any fundamental problem.
- What is the company's financial health based on trailing data?
- Trailing P/E is 14.7, ROE is 15.9%, and the company has zero debt. These metrics are healthy for a nano-cap manufacturer.
- Is this a stock to buy after these results?
- The results are steady but provide no catalyst for re-rating. The market cap is ₹152 crore, and growth is modest. Investors should watch for signs of acceleration before making a move.